Literature DB >> 33132374

Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library.

Chizuru Miura1, Naoya Shindo1, Kei Okamoto2, Keiko Kuwata1, Akio Ojida1.   

Abstract

Fragment-based approach combined with electrophilic reactive compounds is a powerful strategy to discover novel covalent ligands for protein target. However, the promiscuous reactivity often interferes with identification of the fragments possessing specific binding affinity to the targeted protein. In our study, we report the fragment-based covalent drug discovery using the chemically tuned weak reactivity of chlorofluoroacetamide (CFA). We constructed a small fragment library composed of 30 CFA-appended compounds and applied it to the covalent ligand screening for cysteine protease papain as a model protein target. Using the fluorescence enzymatic assay, we identified CFA-benzothiazole 30 as a papain inhibitor, which was found to irreversibly inactivate papain upon enzyme kinetic analysis. The formation of the covalent papain-30 adduct was confirmed using electrospray ionization mass spectrometry analysis. The activity-based protein profiling (ABPP) experiment using an alkynylated analog of 30 (i.e., 30-yne) revealed that 30-yne covalently labeled papain with high selectivity. These data demonstrate potential utility of the CFA-fragment library for de novo discovery of target selective covalent inhibitors.

Entities:  

Keywords:  activity-based protein profiling; chlorofluoroacetamide; covalent inhibitor; cysteine protease; fragment-based drug discovery

Mesh:

Substances:

Year:  2020        PMID: 33132374     DOI: 10.1248/cpb.c20-00547

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  1 in total

1.  Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide.

Authors:  Daiki Yamane; Satsuki Onitsuka; Suyong Re; Hikaru Isogai; Rui Hamada; Tadanari Hiramoto; Eiji Kawanishi; Kenji Mizuguchi; Naoya Shindo; Akio Ojida
Journal:  Chem Sci       Date:  2022-02-15       Impact factor: 9.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.